Oncotype DX Breast DCIS Score^® test

Approximately 20% of all new breast cancers diagnosed in the United States are ductal carcinoma in situ (DCIS),1 and no two DCIS patients—or their tumors—are the same.

A pre-invasive form of breast cancer in which tumor cells are confined to the milk ducts, DCIS is typically non-lethal but treatments—such as surgery, radiation therapy, and hormonal therapy—can cause both short-term and long-term side effects.2

Exact Sciences’ Oncotype DX Breast DCIS Score test enables patients and their providers to personalize their treatment decisions and forego potentially unnecessary treatment, such as radiation, when they have a low score and a low-risk of local recurrence. For those with higher scores, the result confirms that they would likely benefit from a more aggressive local approach to treatment, such as radiation therapy.1, 4, 5, 6

View our patient brochure to learn more about how the Oncotype DX Breast DCIS Score test can help guide treatment decisions for your patients.